Multiple myeloma — multi-cohort phase 2 (1-3 prior lines, early relapse, post-ASCT suboptimal response) — Janssen / Legend Biotech
Visit Interactive Trial Page →
Top tweets by impressions — click to view on X
#mmsm #IMWG25
Summer of the CARTITUDE programs for Cilta Cel https://t.co/u3Wm2uAxPB
“📊 Impact of Prior BCMA-Targeted Therapies on CAR T-Cell Outcomes
🔹 CARTITUDE-2 Cohort C:
•Evaluated Cilta-Cel after PI, IMiD, CD38 mAb, and BCMA-targeted therapy.
•Best ORR:
•Full cohort:…
For US HCPs at #IMS25, see Dr. Yael Cohen present updated results from CARTITUDE-2, Cohort D of a BCMA-directed #CART therapy +/- lenalidomide maintenance for multiple myeloma patients with a…
CARTITUDE-2 provides cohort-specific evidence for cilta-cel in earlier treatment lines (including len-refractory mm post-1-3 lines and post-ASCT suboptimal responders). Complements CARTITUDE-4 pivotal phase 3 which established the ≥1 prior line approval. Informs clinical decision-making for patient selection.
Cohort A (len-refractory, 1-3 prior lines): ORR 95% (initial)/91% (expansion), 100% MRD negativity at 10⁻⁵ in evaluable patients, 24-month PFS 75%. Cohort B (early relapse): deep responses including 74% sCR, 93% MRD-negative at 10⁻⁵, 24-month PFS 73%. Cohort D (post-ASCT suboptimal response): 36-month outcomes reported with favorable PFS/OS.
Medians not reached across cohorts A/B (median follow-up ~29 months). Cohort A 12-month OS 91%; Cohort B 24-month OS 75-84%. Long-term follow-up continues.
Key AEs: Cytokine release syndrome (CRS), ICANS, other neurotoxicities. Most CRS and ICANS events resolved across all cohorts. No new CAR-T safety signals vs. CARTITUDE-1. Delayed non-ICANS neurotoxicities (movement and neurocognitive events) remain a CARVYKTI class effect requiring monitoring.
⚠️ Supportive phase 2 data — not the basis of FDA approval. CARTITUDE-2 provides cohort-specific evidence for cilta-cel in earlier treatment lines (including len-refractory mm post-1-3 lines and post-ASCT suboptimal responders). Complements CARTITUDE-4 pivotal phase 3 which established the ≥1 prior line approval. Informs clinical decision-making for patient selection.